Fujirebio Diagnostics Inc announces the appointment of Grady Barnes, PhD as chief scientific officer. Dr Barnes comes to the company with 25 years of diagnostics experience. He has held various positions at Abbott and Meridian Bioscience, most recently as vice president of research and development at Meridian Bioscience.
As Chief Scientific Officer, Dr Barnes will be responsible for all scientific affairs including research and development, product development, process engineering and clinical and regulatory affairs. He will also assist in the selection of new product candidates and licensing opportunities for Fujirebio Diagnostics products.
"Dr Barnes’ extensive experience in diagnostics will be vital to sustaining Fujirebio Diagnostics’ growth," says Paul Touhey, president and CEO of Fujirebio. "His expertise will support the growth and acceptance of biomarker assays in ovarian cancer, such as HE4, and help Fujirebio Diagnostics identify additional promising biomarkers in oncology."
Barnes received a Bachelor of Arts degree in natural sciences from Johns Hopkins University, and his PhD in biochemistry from Florida State University. He has directed the commercialization of over 50 products, including diagnostic assay kits, hardware, and software.
Fujirebio Diagnostics specializes in the clinical development, manufacturing, and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology.
Source: Fujirebio Diagnostics
